Biomarkers in oncology indications approved in the EU: key facts

15th Industry Standing Group (ISG) meeting, Online, European Medicines Agency, Amsterdam, the Netherlands, from 11 December 2025, 09:00 (CET) to 11 December 2025, 10:00 (CET)

EMA multi-stakeholder workshop on supporting innovation in cardiovascular medicines and medical devices in the EU, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 1 July 2026, 13:00 (CEST) to 2 July 2026, 16:00 (CEST)

EMA multistakeholder workshop on supporting innovation in cardiovascular medicines and medical devices in the EU, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 1 July 2026 to 2 July 2026

Human medicines European public assessment report (EPAR): Clopidogrel Viatris (previously Clopidogrel Taw Pharma), clopidogrel, Date of authorisation: 16/10/2009, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR): Prialt, ziconotide, Date of authorisation: 21/02/2005, Revision: 32, Status: Authorised

Human medicines European public assessment report (EPAR): Synagis, palivizumab, Date of authorisation: 13/08/1999, Revision: 46, Status: Authorised

Human medicines European public assessment report (EPAR): Azacitidine Mylan, azacitidine, Date of authorisation: 27/03/2020, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Imaavy, nipocalimab, Date of authorisation: 28/11/2025, Status: Authorised

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 8-11 December 2025